BCRX logo

BCRX
Biocryst Pharmaceuticals Inc.

36,414
Mkt Cap
$1.65B
Volume
3.2M
52W High
$11.31
52W Low
$6.00
PE Ratio
-160.47
BCRX Fundamentals
Price
$7.59
Prev Close
$7.83
Open
$7.84
50D MA
$7.14
Beta
1.00
Avg. Volume
4.55M
EPS (Annual)
-$0.43
P/B
-4.12
Rev/Employee
$777,089.66
Loading...
Loading...
News
all
press releases
BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership
Arrowstreet Capital Limited Partnership grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2,103.7% in the 2nd quarter, according to the company in its most recent...
MarketBeat·2h ago
News Placeholder
More News
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 19,770 shares of the business's stock in a transaction on Wednesday, December 3rd. The stock was sold at an...
MarketBeat·1d ago
News Placeholder
Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 50,906 shares of the company's stock in a transaction dated Tuesday, December 2nd. The stock was sold at an...
MarketBeat·1d ago
News Placeholder
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·2d ago
News Placeholder
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·2d ago
News Placeholder
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·2d ago
News Placeholder
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·2d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $646,128.40 in Stock
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 91,004 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, December 1st. The shares were...
MarketBeat·2d ago
News Placeholder
Jefferies Financial Group Inc. Makes New Investment in BioCryst Pharmaceuticals, Inc. $BCRX
Jefferies Financial Group Inc. purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·8d ago
News Placeholder
Neo Ivy Capital Management Takes $810,000 Position in BioCryst Pharmaceuticals, Inc. $BCRX
Neo Ivy Capital Management bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure...
MarketBeat·13d ago

Latest BCRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.